The EUA was supported by primary data from the phase 3 PROVENT trial. The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with ...
For several years, pre-exposure prophylaxis against HIV (PrEP) has been a major success in preventing new cases. However, individuals on PrEP typically engage in riskier sexual behavior and thus are ...
Pre-exposure prophylaxis (PrEP) has emerged as a transformative biomedical intervention capable of reducing HIV transmission risk by up to 99% when adherence is optimal. Initially piloted in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results